BiomX receives NYSE non-compliance notice over equity deficits. Company must submit a plan by April 24, 2026, or risk delisting amid financial pressure.
FDA approves Icotyde, J&J’s once-daily psoriasis pill, offering an oral alternative to costly injectable drugs like Tremfya and Skyrizi.
